Tumor-reactive CD4 + T helper (Th) cells play a critical role in antitumor immunity, due to their ability to induce CD8 + T cell-mediated cytotoxic activity and humoral response. This study focuses on the in vitro generation and expansion of Th cells specific for the tumor-associated antigen 'human epidermal growth factor receptor-2' (HER2). A protocol for efficient HER2 presentation was developed using autologous monocyte-derived dendritic cells (DC) as antigen presenting cells (APC) and purified HER2 protein as antigen source. Our data suggest that DC pulsed with recombinant protein of the extracellular domain (ECD) of HER2 (ECD/HER2) induce an ECD/HER2-specific Th cell response. This finding may facilitate the development of immunotherapy regimens without requiring defined immunogenic epitopes of the antigen.
Introduction
In animal models, established tumors can be eradicated by the adoptive transfer of T cells specific for tumor-associated antigens (TAA) (Greenberg, 1986; Hanson et al., 2000; Shu and Rosenberg, 1985) . Furthermore, several clinical studies have demonstrated that humoral and T cell immunity exist in single cancer patients (Disis et al., 1994a; Linehan et al., 1995) . The aim of eradicating tumors in humans by immunotherapy led to the development of protocols for the efficient generation and expansion of tumor-reactive cytotoxic T lymphocyte (CTL) and Th cell clones (Brossart et al., 2000; Thurner et al., 1999) .
The tumor-specific immune response is based on the ability of dendritic cells (DC) to engulf dead tumor cells and to process TAA for major histocompatibility complex (MHC)-restricted antigen presentation (Albert et al., 1998; Nouri-Shirazi et al., 2000) . After antigen uptake, DC mature and migrate to lymphoid organs, where they present antigenic peptides to T cells (for review, see Banchereau and Steinman, 1998) .
Two signals are required for full activation of T cells. The first signal, providing the antigen specificity to a T cell response, is the engagement of the T cell receptor by the MHC-peptide complex. Secondly, a costimulatory signal is delivered by interaction between the T cell molecule CD28 and its ligands CD80 and CD86 on mature DC (for review, see Lenschow et al., 1996) .
Upon activation, antigen-specific T cells proliferate and differentiate into effector T cells. The primed T cells re-enter the circulation and perform their effector functions after a second antigen challenge (Butcher and Picker, 1996) .
The existence of T cells, specific for HER2, in patients suffering from breast cancer could be demonstrated (Fisk et al., 1994; Peoples et al., 1995) . The HER2 proto-oncogene encodes for a 185 kDa receptor tyrosine kinase with high homology to the 'epidermal growth factor receptor' (EGFR) (Coussens et al., 1985) . HER2 has been detected in subsets of a wide range of cancers, e.g. adenocarcinomas of breast, ovary, colon and lung (Hynes and Stern, 1994; Slamon et al., 1989) . Overexpression of HER2 contributes to the malignant phenotype of the tumor and is associated with poor prognosis (Slamon and Clark, 1988) .
The good accessibility on the surface of tumor cells and the existence of humoral and T cell immunity in some cancer patients makes HER2 an attractive target for immunotherapy (Disis et al., 1994b) . The goal of this work was to develop a protocol for the in vitro induction of a Th cell immunity to HER2. For this purpose, we have established a T cell priming model using monocyte-derived dendritic cells as APC and highly purified recombinant HER2 protein as antigen source.
Materials and methods

Production of recombinant protein and cell lysate preparation
Chinese hamster ovary (CHO) cells were transfected with a methotrexate-selectionable expression vector containing the polyhistidine-tagged cDNA of either the lymphocyte-activation antigen-3 (LAG-3), ECD/EGFR or ECD/HER2. The cells were initially cultivated in alpha minimal essential medium (MEM, Gibco BRL, Karlsruhe, Germany), supplemented with 10% heat-inactivated dialysed fetal calf serum (FCS, PAA Laboratories, Cölbe, Germany), 100 IU ml-1 penicillin, 100 IU ml-1 streptomycin, 2 mM Lglutamine (all from Gibco BRL) and 100 nM methotrexate (Medac, Hamburg, Germany), and then transferred into the protein-free Rencyte K1-medium (MediCult, Jyllinge, Denmark), supplemented with 100 IU ml-1 penicillin, 100 IU ml-1 streptomycin and 100 nM methotrexate. After the adaptation phase the transfected CHO cells were cultivated to high density (1-2 × 10 8 cells) in the miniPERM bioreactor (Vivascience, Hannover, Germany).
The secreted recombinant proteins were purified from the cell culture supernatant using a metal chelate affinity chromatography column. To improve binding to Nickel-NTA resin (Qiagen, Hilden, Germany) components of the medium with potentially reducing activity were removed by dialysis against PBS with the crossflow-filtration modules Vivaflow50 (Vivascience).
Identity of the purified proteins was confirmed by immunoblot analysis with the polyhistidine-specific antibody Penta-His (Qiagen) and purity was proven to be > 95% by detection of protein bands with Brillant Blue R (Sigma, Deisenhofen, Germany).
Recombinant ECD/HER2 produced in a mouse L-cell expression system was a gift from Dr. T. Vedvick (Corixa, Seattle, WA). The protein is identical to ECD/HER2 derived from transfected CHO cells with the exception of the absence of a polyhistidine-tag and was purified from the cell culture supernatant by Con A Sepharose and anion-exchange chromatography. The protein preparation was proven to be of high purity in reverse phase HPLC and gel electrophoresis (T. Vedvick, personal communication).
Native and HER2-transfected NIH3T3-fibroblasts were obtained from the American Type Culture Collection (ATCC, Manassas, VA) and cultured in DMEM (Gibco BRL) supplemented with 10% heatinactivated FCS, 100 IU ml-1 penicillin, 100 IU ml-1 streptomycin and 2 mM L-glutamine. Cell lysates were prepared by resuspending 1 × 10 6 fibroblasts in 200 µl distilled water followed by three cycles of freezing in liquid nitrogen and thawing. Coulter) were used as isotype controls. HER2 expression levels of native and transfected NIH3T3-fibroblasts were determined in a two-step procedure with the mouse anti-human HER2 mAb TA-1 (Oncogene Science, Boston, MA) and a FITC conjugated F(ab') 2 -fragment of goat anti-mouse IgG (Zymed Laboratories, San Francisco, CA). Fluorescence analyses were performed on an Epics Elite ESP flow cytometer (Coulter Electronics, Hialeah, FL) using forward and side scatter properties to exclude dead cells.
Flow cytometric analysis
Generation of antigen-loaded mature and immature DC
Monocyte-derived DC were generated according to a method described by Jonuleit et al. (1997) . In brief, peripheral blood mononuclear cells (PBMC) from a healthy donor were isolated by Ficoll density gradient centrifugation. Monocytes were isolated by plastic adherence and cultured in X-VIVO-15 (BioWhittaker, Walkersville, MD) supplemented with 1% heatinactivated autologous plasma, 2 mM L-glutamine, 1600 IU ml-1 GM-CSF (Sandoz, Nürnberg, Germany) and 1000 IU ml-1 IL-4 (Strathmann-Biotech, Hannover, Germany). On day 7, the non-adherent DC precursor were rinsed off, washed once with medium and transferred to fresh 6-well plates (Greiner, Nürtin-gen, Germany) at 5 × 10 5 cells in 3 ml medium per well. Subsequent to the addition of 75 µg of purified ECD/HER2 protein, DC maturation was induced with 1 µg ml-1 prostaglandin E 2 (PGE 2 , Pharmacia & Upjohn, Kalamazoo, MI) and the following proinflammatory cytokines: 10 ng ml-1 TNF-α, 10 ng ml-1 IL-1β, 1000 IU ml-1 IL-6 (all from StrathmannBiotech), 500 IU ml-1 IL-4 and 800 IU ml-1 GM-CSF. The ECD/HER2-loaded mature DC were exclusively used to induce a HER2-specific response of naive CD4 + T cells. For restimulation and for subsequently performed functional testing antigen-loaded immature DC were added to the T cell culture. The latter were generated by cultivation of antigen-loaded DC precursor in X-VIVO medium supplemented with 1600 IU ml-1 GM-CSF and 1000 IU ml-1 IL-4 as the only cytokines. On day 10, mature and immature DC were analyzed for MHC and costimulatory molecule expression and used as stimulator cells.
Analysis of antigen processing by DC in immunofluorescence microscopy
For analysis of antigen processing by immature DC, 5 mg ECD/EGFR protein were labeled with a 50 molar excess of the fluorescein-hydroxysuccinimide ester FLUOS (Roche, Mannheim, Germany). After 2 h of incubation at RT, the protein was separated from unbound dye by size-exclusion using a G 25-Sepharose column (Roche). DC were loaded with the fluorescein-labeled protein at 37 • C for various times (30 min, 2 h, 4 h, 8 h and 36 h) and transferred on poly-lysine (Sigma) coated Lab-Tek chamber slides (Nalge Nunc, Naperville, IL) at a density of 5 × 10 4 cells per chamber. The cells were fixed on the slides with 2% paraformaldehyde (Sigma) for 10 min at RT and permeabilised with methanol for 2 min. After blocking in 10% goat serum (Sigma) for 1 h at RT, the slides were incubated overnight at 4 • C in 10% goat serum with 20 µg ml-1 of either the mannose receptor-specific mAb 19, the LAMP-1-specific mAb H4A3 or the HLA-DR-specific mAb TÜ36 (all from BD PharMingen). Subsequently, cells were exposed to a Texas Red-conjugated goat anti-mouse secondary antibody (Dianova, Hamburg, Germany) in a 1:200-dilution with 10% goat serum for 1 h at RT. Following incubation in DAPI (Sigma, 1 µg ml-1 in PBS, 5 min at RT) to stain nuclei, the slides were mounted using the Slow Fade Antifade Kit (Molecular Probes, Eugene, OR). For visualization, a Zeiss Axioskop microscope (Zeiss, Göttingen, Germany) was used with appropriate filters.
Generation of B-lymphoblastoid cell lines (LCL)
PBMC were incubated for 2 h in the Epstein-Barr virus-containing culture supernatant of the marmoset cell line B95-8 (ATCC, Rockville, MD). Two weeks after the addition of RPMI 1640 medium (Gibco BRL) supplemented with 10% heat-inactivated FCS, 100 IU ml-1 penicillin, 100 IU ml-1 streptomycin, 2 mM Lglutamine and 1 µg ml-1 cyclosporin A (Sigma), cell aggregates became visible indicating the occurrence of LCL.
LCL from long-term cultures were harvested and seeded in a cell number of 5 × 10 5 per well in roundbottom 96-well plates (Greiner). After addition of 5 µg recombinant protein and 20 h of incubation, LCL were irradiated with 80 Gy and used as stimulator cells for T cell expansion.
Isolation and expansion of a HER2-specific CD4 + Th cell clone CD4 + T cells were enriched from the PBMCpreparation of a healthy donor by magnetic cell sorting (MACS) with a CD4-specific antibody (Miltenyi Biotec, Bergisch-Gladbach, Germany). 1 × 10 6 CD4 + T cells were cocultured with 2 × 10 4 ECD/HER2-pulsed autologous DC per well in 24-well plates (Greiner) in RPMI 1640 medium with 5% autologous serum, 100 IU ml-1 penicillin, 100 IU ml-1 streptomycin and 2 mM L-glutamine, termed T cell medium (TCM). The T cells of each well were cultured separately. Three cycles of weekly restimulations with protein-loaded immature DC in TCM supplemented with 20 IU ml-1 IL-2 (R & D Systems, Wiesbaden, Germany) and 5 ng ml-1 IL-7 (BD PharMingen) were performed to further expand HER2-specific T cells. Between the first and second restimulation, the T cell cultures were transferred to 96-well plates with 1 × 10 5 T cells per well. After the third cycle of restimulation the cultures were tested for ECD/HER2-specific IFN-γ release in ELISPOT-analysis. Activated T cells of the microculture F2, showing the optimum HER2-specific response, were enriched by MACS using the IFN-γ secretion assay and anti-PE paramagnetic beads (Miltenyi Biotec). The sorted polyclonal T cells (T cell line F2) were further cultivated and stimulated. To provide factors for optimal growth of the F2 T cells, 20 IU ml-1 IL-2, 5 ng ml-1 IL-7 and 5% TStim (BD PharMingen) were added to the TCM in all subsequent cultivation steps. After proving the HER2-specificity with the IFN-γ secretion assay, the relative frequency of TCR Vβ-motifs in the F2 T cell culture was determined by flow cytometric analysis with a panel of TCR Vβ-specific antibodies (Beckman Coulter). TCR Vβ5.3-positive T cells, which resembles 85% of the total T cell population, were enriched by MACS using the PE-conjugated anti-TCR Vβ5.3-specific antibody 3D11 (Beckman Coulter) and anti-PE paramagnetic beads (Miltenyi Biotec). Sorted T cells were cloned directly by limiting dilution with 0.3 cells per well in round-bottom 96-well plates in the presence of 1 × 10 5 ECD/HER2-pulsed irradiated autologous LCL as stimulator cells. The Th cell clone F2.5, demonstrating best viability and IFN-γ release upon antigen-specific stimulation, was further expanded to high cell numbers by coincubation with 15 × 10 6 ECD/HER2-pulsed irradiated autologous LCL in T 30 -flasks (Greiner).
Screening of Th cell cultures with the IFN-γ enzyme linked immunospot (ELISPOT)-assay
1 × 10 3 T cells and 2 × 10 4 protein-loaded DC were cocultured overnight at 37 • C in the wells of 96-well nitrocellulose filter plates (Millipore, Bedford, MA) coated with the mouse anti-human IFN-γ antibody 1-D1K (Mabtech, Nacha, Sweden). After removal of cells by washing with PBS, captured IFN-γ was detected by the sequential addition of the biotinylated anti-IFN-γ antibody 7-B6-1 (Mabtech), horseradish peroxidase-conjugated streptavidin (ABC VectastainElite Kit, Vector, Burlingame, CA) and the peroxidase substrate aminoethylcarbazole (AEC, Sigma) (for details, see Herr et al., 1996) . Red spots corresponding to single IFN-γ -secreting cells were counted by dissecting microscopy (Zeiss, Göttingen, Germany).
Measurement of effector T cell responses with the IFN-γ secretion assay
1 × 10 5 T cells were stimulated with 1 × 10 4 proteinpulsed DC per well in round-bottom 96-well plates 12 h prior to analysis. IFN-γ , secreted within 45 minutes, was captured on the surface of activated cells by an anti-IFN-γ x CD45 Fab-trimer construct (Miltenyi Biotec). For flow cytometric analysis, the T cells were stained with a PE-conjugated anti-IFN-γ mAb (Miltenyi Biotec) and the FITC-conjugated anti-CD4 mAb 13B8.2 (Beckman Coulter). Non-viable cells were excluded from analysis by staining with 2 µg ml-1 propidium iodide (Sigma). The three color analysis was performed on an Epics Elite ESP flow cytometer (Coulter Electronics).
Results and discussion
Establishment of a cell culture procedure for the isolation of soluble protein antigens
Cultures of CHO cells transfected with a plasmid vector containing the coding sequences for the LAG-3, ECD/EGFR and ECD/HER2 protein were established under serum-and protein-free conditions. Without serum supplement the CHO cells lost their capacity to adhere on the plastic surface of the culture vessel and grew in suspension forming small cell aggregates. Microscopic examination with trypan blue dye suggested that these cell aggregates were almost free of dead cells. 5 × 10 7 cells were transferred into the production module of a bimodular minifermenter. During Figure 1 . Phenotypic characterization of in vitro generated monocyte-derived DC by flow cytometry. Differentiation was induced by adding PGE 2 and the cytokines IL-4, GM-CSF, TNF-α, IL-1β and IL-6 to FCS-free cell culture medium. After 9 days of in vitro culture, the monocyte-specific marker CD14 was completely down-regulated. The high expression level of MHC class II-molecules, the mature phase marker CD83, the costimulators CD80 and CD86 and the adhesion molecules CD54 indicates the high capability of mature DC to initiate an antigen-dependant Th cell response. The empty curve represent the appropriate isotype-matched antibody.
rotary culture CHO cells continued to proliferate, and after one week the total number of viable cells were in the range of 1-2 × 10 8 cells with less than 10% dead cell contaminants. Compared to stationary cultures in cell culture flasks and cell factories, the culture supernatant contained higher titer of secreted recombinant protein.
The establishment of this high density CHO culture in serum-and protein-free medium was the prerequisite for obtaining pure recombinant proteins in the subsequent one-step FPLC column purification protocol. For efficient binding of the histidine-tagged recombinant proteins to nickel-coated agarose beads, the cell culture supernatants were dialysed and concentrated using tangential flow-filtration modules. To prevent degradation of recombinant ECD/HER2 protein, low imidazole concentrations (80 mM) were used for elution. Starting with 150 ml of cell culture supernatant, an amount of 0.5-2 mg of pure protein was yielded by this purification procedure.
Determination of T cell stimulatory and antigen-processing capacity of in vitro generated DC
In vitro generated monocyte-derived immature DC were loaded with the recombinant ECD/HER2-protein. The cells were differentiated into mature DC with a cocktail of pro-inflammatory cytokines and PGE 2 . At this stage, the conversion of monocytes into DC was indicated by the complete down-regulation of the monocyte and macrophage lineage specific CD14 marker and the induction of CD83 surface expression (Fig. 1) . Because of its DC-restricted expression, the CD83 molecule, which is not well characterized in its function, served as the marker indicating the completeness of DC differentiation (Zhou and Tedder, 1995) . Due to the high surface expression of the MHC-encoded HLA-DR molecule the formation of large amounts of MHC class II-peptide complexes was displayed. The in vitro generated mature DC also expressed various accessory molecules at high density that might interact with receptors on T cells for enhancing adhesion and signaling. The costimulatory Figure 2 . For studying the intracellular localization of exogenous antigen in immunofluorescence microscopy, immature DC, generated from blood monocytes, were pulsed with FITC-conjugated recombinant ECD/EGFR (green). After fixation and permeabilisation DC were incubated with monoclonal antibodies for the cellular marker mannose receptor, LAMP-1 and HLA-DR and stained with a Texas Red-labeled secondary Ab (red). In a color overlay the colocalisation of ingested antigen and the cellular marker LAMP-1 and HLA-DR is indicated in yellow. For better orientation nuclei were stained with DAPI (blue). molecules CD80 and CD86 play a key role for induction of primary T cell responses by providing a second signal through their binding of the CD28 molecule on naive T cells. High expression rates of the adhesion molecule CD54, which interacts with the LFA-1 receptor on T cells, drives the development of primed CD4 + T cells towards the Th1 phenotype. Because Th1 cells support TAA-specific cytotoxic T cells to lyse tumor cells, this functional polarization is another essential event for the induction of antitumor immunity.
The endocytotic pathway of ingested protein antigens was determined in immunofluorescence microscopy. The FITC-labeled ECD/EGFR protein was detectable 4 h after antigen addition in LAMP-1-and HLA-DR-positive vesicles by extensive colocalisation with the individual markers in a color overlay (Fig.  2) . This indicates, that the engulfed protein antigen was rapidly directed to the MHC class II-rich compartment (MIIC), a DC-restricted lysosome-like cell compartment specialized in protein degradation and MHC-peptide complex formation.
Despite the fact that the recombinant ECD/EGFR is highly glycosylated, the antigen uptake was not mediated by the C-type lectin receptor macrophage mannose receptor (Fig. 2) . This molecule is localized on the cell surface and in early endosomes of DC. Ingestion of the ECD/EGFR protein may therefore be driven mainly by a DC-specific process, so-called micropinocytosis and first described by Sallusto et al. (1995) . The capability of immature DC to form large pinocytic vesicles in which extracellular fluid and solutes are sampled is a very efficient mechanism to capture any small particle and soluble antigen and to direct it to the MIIC. 
Induction of a HER2-specific Th cell response and isolation of the HER2-specific Th1 cell clone F2.5
The mature DC, pulsed with ECD/HER2, induced primary responses of naive T cells in a culture of CD4-sorted lymphocytes. The responder T cells received three additional weekly restimulations with ECD/HER2-loaded immature DC in the presence of IL-2 and IL-7. An overview of the procedure used to obtain ECD/HER2-specific CD4 + T cells is given in Figure 3 . In the early culture period many T cells undergo apoptosis. However, three days after the first restimulation, clusters of proliferating cells surrounding the larger DC were detectable under a microscope.
The cultures were initially set up in 24-well plates with 1 × 10 6 T cells and 1 × 10 4 DC per well because of the large number of freshly isolated CD4 + T cells. T cells of one well, termed microcultures, were cultivated separately from each other. During apoptosis, found to be maximum between the first and second restimulation, the cells of the microcultures were transferred into round-bottom 96-well plates with 1 × 10 5 T cells per well to bring activated T cells in close contact to each other.
The cultures were tested 20 h after the third restimulation for HER2-specific IFN-γ production in an ELISPOT assay. Most of the cultures showed no differences between untreated and ECD/HER2-loaded immature DC, indicating that surface structures of the in vitro generated DC are more likely to activate CD4 + T cells than it does the ECD/HER2 protein itself. Only a small fraction displayed more IFN-γ spots in the presence of ECD/HER2-pulsed DC. The T cell culture F2, showing the strongest ECD/HER2-specific signal, was chosen for further characterization. The IFN-γ -secreting F2 T cells were isolated by MACS 16 h after restimulation with ECD/HER2-loaded immature DC. This culture was further expanded by repeated weekly restimulations.
To enhance the expansion capacity of F2 T cells, several cytokines and medium supplements were tested. Medium containing 20 IU ml-1 IL-2, 5 ng ml-1 IL-7 and 5% of a conditioned medium from activated human PBMC, termed T-Stim, was proven to be superior for T cell expansion.
In an IFN-γ secretion assay, the F2 T cells reacted to ECD/HER2 or lysate of HER2-transfected NIH3T3-cells, but not to the heterogeneous protein mixture FCS or lysate of native NIH3T3-cells (Fig. 4) .
As depicted in Figure 4 , the F2 T cell line contained a population of CD4-negative lymphocytes. These cells were further characterized as CD8 + T cells by flow cytometric analysis. Further examination indicated that these cells were contaminants of the DC preparation. Therefore, a method to distinguish HER2-specific T cells from other T cells was of utmost interest. One option was to characterize the TCR motif used by the HER2-specific T cells. A flow cytometric analysis with a panel of TCR Vβ-specific antibodies revealed that 85% of the F2 cells were positive for the TCR Vβ5.3-restricted motif IgRb08. For this reason, cells were sorted with the IgRb08-specific antibody 3D11 and directly cloned by limiting dilution with 0.3 T cells per well using ECD/HER2-pulsed irradiated autologous LCL as stimulator and feeder cells. After two weeks of culture in 96-well plates, 12 out of 120 plated clones proliferated. In the subsequent cultivation procedure, 10 of these microcultures could not be further expanded, suggesting that activation-induced cell death occurs upon stimulation. Only one clone, designated as F2.5, depicted good viability and was selected for further expansion.
In the IFN-γ secretion assay, F2.5-cells responded considerably to recombinant ECD/HER2 of two different sources, but not to the irrelevant protein LAG-3. The ECD/EGFR protein with 60% HER2-homology and the heterogeneous protein mixture FCS only provoked a modest T cell response (Fig. 5) . A flow cytometric analysis with the mAb 3D11 showed that all cells were IgRb08-positive, proving their clonal origin. By coincubation with 15 × 10 6 ECD/HER2-pulsed irradiated autologous LCL as stimulator cells, 5 × 10 5 T cells of the F2.5 clone could be expanded to cell numbers of 1-2 × 10 7 cells per flask within two weeks. Because antigen-loaded LCL were irradiated, the responder T cells were the only proliferating cells in the culture. Moreover, the responder T cells possessed a moderate lytic activity against the antigenloaded B cells leading to a homogeneous T cell culture after the two week expansion period.
Conclusions
Current vaccination protocols have been based on the activation of MHC class I-restricted CD8 + T cells with peptide-loaded DC (Brossart et al., 2000; Jäger et al., 1996; Thurner et al., 1999) . Results obtained from these studies lead to the conclusion that their efficacy have been limited due to the inadequate induction of Th responses. Furthermore, studies in animal models have demonstrated that the vaccination with epitopes for both tumor-specific helper and cytotoxic T cells results in fast and efficient tumorlysis (De Veerman et al., 1999; Ossendorp et al., 1998) . We successfully induced a Th cell response against HER2 and generated an ECD/HER2-specific Th cell clone in vitro. Thus, the adoptive transfer of HER2-reactive Th cell clones in combination with HER2-specific CTL clones is an applicable method for an improved immunotherapy in patients with HER2-overexpressing cancer. The identification of the peptide epitope that provokes the T cell response of the F2.5-clone will be helpful for current strategies. With the knowledge of the T cell-defined amino acid sequence, the synthesized peptide can be used for generating specific T cells using peptide-loaded DC. Furthermore, the generation of MHC class II-peptide tetramers based on this amino acid sequence will facilitate the detection and isolation of reactive T cells from blood samples of patients with HER2-overexpressing tumors by flow cytometric-and cell sorting-techniques (Altman et al., 1996; Yee et al., 1999) . Ongoing studies have to focus on defining the immunogenic peptide motif and the MHC restriction element used by the F2.5-clone.
